“Masking” is part of life, especially for those with autism or A.D.H.D. But hiding your true self comes with a cost. Credit...Vanessa Saba Supported by By Christina Caron When Amara Brook was training ...

Casino operator Affinity Interactive is in talks with Moelis & Co. for advice as it looks to negotiate with bondholders over a potential restructuring, according to people familiar with the matter.

What if you could transform your entire creative workflow with just one update? That’s exactly what Affinity promises with its biggest update ever, a bold leap forward that’s turning heads across the ...

Affinity has all the same editing tools as Affinity Photo, but with vector drawing and page layout thrown in, too. Affinity is a technical, professional program, however, so don’t expect quick fixes ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

After acquiring Serif last year, Canva has overhauled its Affinity design suite, consolidating three creative tools into a single free app for Mac and Windows. The newly launched Affinity by Canva ...

Affinity, the popular Adobe alternative developed by Serif, has officially resurfaced under Canva’s ownership as a single, all-in-one creative platform. Following Canva’s acquisition of Serif in 2024, ...

And Canva really, really wants you to know that it’s completely free. And Canva really, really wants you to know that it’s completely free. is a news writer focused on creative industries, computing ...

The popular three Affinity design apps on Mac and Windows both have been scrapped, as Canva combines all previous functions into a single and completely free Mac app. Now that announcement and the ...

When graphic design platform-provider Canva bought the Affinity image-editing and publishing apps early last year, we had some major questions about how the companies’ priorities and products would ...

Therapeutic monoclonal antibodies (mAbs) constitute cornerstone therapeutics in oncology, yet their clinical utility is often limited by on-target, off-tumor toxicity due to shared antigen expression ...